Targeting STAT3 Signaling for Immune Checkpoint Blockade to Augment PARP Inhibitor Therapy in BRCA-Mutated Ovarian Cancer PARP inhibitors and immune checkpoint inhibitors are two promising new therapies for ovarian cancer patients who have mutations in the BRCA gene. BRCA-mutated ovarian cancer cells produce a protein called PD-L1 to avoid being recognized and killed by immune […]
Read More